CNS(중추신경계) 치료제 시장 규모, 점유율, 성장 분석 : 질환별, 약제 클래스별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
CNS (Central Nervous System) Therapeutics Market Size, Share, and Growth Analysis, By Disease (Neurovascular Diseases, CNS Trauma), By Drug Class (Anesthetics, Anticonvulsants), By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1663122
리서치사:SkyQuest
발행일:2025년 02월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
CNS(중추신경계) 치료제 2023년 시장 규모는 1,363억 7,000만 달러로, 2024년 1,449억 6,000만 달러에서 2032년에는 2,363억 3,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 6.3%로 추이할 전망입니다.
세계 중추신경계(CNS) 치료제 시장은 빠르게 발전하고 있으며, 다양한 신경질환 및 정신질환에 대한 치료 확대가 이루어지고 있습니다. 정신건강 문제에 대한 인식이 높아지고 고령화가 진행됨에 따라 이 분야는 큰 성장세를 보이고 있습니다. 지속적인 연구개발 노력으로 치료 접근법이 강화되고 있으며, 제약회사와 연구기관의 전략적 제휴가 혁신을 촉진하고 있습니다. 기술이 발전함에 따라 중추신경계 치료제 시장은 많은 사람들의 삶의 질을 향상시킬 준비가 되어 있습니다. 그러나 규제 상황, 가격 압력, 경쟁 구도와 같은 과제도 존재하며, 복잡한 업계 상황을 성공적으로 극복하기 위해서는 이해관계자들의 전략적 대응이 필요합니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
CNS(중추신경계) 치료제 시장 규모 : 질환별 & CAGR(2025-2032)
시장 개요
신경혈관 질환
중추신경계 외상
정신건강
불안장애
간질
기분 장애
정신병성 장애
기타
신경변성질환
알츠하이머병
파킨슨병
다발성 경화증
헌팅턴병
근위축성측색경화증
기타
감염증
중추신경계 암
기타
CNS(중추신경계) 치료제 시장 규모 : 약제 클래스별 & CAGR(2025-2032)
시장 개요
마취제
항경련약
항구토제
중추 신경 자극약
진통제
기타
CNS(중추신경계) 치료제 시장 규모 : 유통 채널별 & CAGR(2025-2032)
시장 개요
병원 약국
소매 약국
기타
CNS(중추신경계) 치료제 시장 규모 : 지역별 & CAGR(2025-2032)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
기업의 상세
제품 포트폴리오 분석
기업의 부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
Biogen(United States)
Otsuka Pharmaceutical Co., Ltd.(Japan)
Eli Lilly and Company(United States)
Merck & Co., Inc.(United States)
AstraZeneca(United Kingdom)
Takeda Pharmaceutical Company Limited(Japan)
Novartis AG(Switzerland)
Teva Pharmaceutical Industries Ltd.(Israel)
Johnson & Johnson Services, Inc.(United States)
Pfizer Inc.(United States)
Sanofi S.A.(France)
H. Lundbeck A/S(Denmark)
UCB S.A.(Belgium)
PTC Therapeutics(United States)
Jazz Pharmaceuticals plc(Ireland)
Acadia Pharmaceuticals, Inc.(United States)
Neumora Therapeutics(United States)
Immunic Therapeutics(United States)
Muna Therapeutics(Denmark)
NRG Therapeutics(United Kingdom)
결론과 제안
KSA
영문 목차
영문목차
CNS (Central Nervous System) Therapeutics Market size was valued at USD 136.37 billion in 2023 and is poised to grow from USD 144.96 billion in 2024 to USD 236.33 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).
The Global Central Nervous System (CNS) Therapeutics market is rapidly evolving, addressing a variety of neurological and psychiatric disorders through an expanding array of treatments. Driven by increased awareness of mental health issues and an aging population, this sector is experiencing significant growth. Ongoing research and development efforts are enhancing therapeutic approaches, while strategic collaborations between pharmaceutical firms and research institutions are fostering innovation. As technological advancements continue, the CNS therapeutics market is poised to improve the quality of life for many individuals. However, challenges such as regulatory hurdles, pricing pressures, and intense competition necessitate strategic responses from industry stakeholders to navigate the complex landscape successfully.
Top-down and bottom-up approaches were used to estimate and validate the size of the CNS (Central Nervous System) Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global CNS (Central Nervous System) Therapeutics Market is segmented by Disease, Drug Class, Distribution Channel and region. Based on Disease, the market is segmented into Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer and Others. Based on Drug Class, the market is segmented into Anesthetics, Anticonvulsants, Antiemetics, CNS Stimulants, Pain Relievers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the CNS (Central Nervous System) Therapeutics Market
The global aging population is a key driver for the Central Nervous System (CNS) therapeutics market, as an increase in age correlates with a higher incidence of neurological disorders such as Alzheimer's and Parkinson's disease. This demographic transformation creates a substantial demand for effective CNS treatments and therapies, given that elderly individuals face a greater risk of developing these debilitating conditions. Consequently, the growing prevalence of age-related neurological disorders underscores the urgent need for innovative CNS therapeutics, prompting advancements in research and development to address the healthcare challenges associated with this rising population segment.
Restraints in the CNS (Central Nervous System) Therapeutics Market
The Central Nervous System (CNS) Therapeutics market faces significant restraints primarily due to the complex nature of developing drugs and treatments for neurological and psychiatric disorders. The process necessitates extensive clinical trials and encounters multiple regulatory challenges, resulting in considerable scrutiny from authorities. This rigorous oversight can cause substantial delays in the approval process and escalate costs associated with bringing new therapies to market. Consequently, these barriers hinder not only innovation within the field but also restrict timely access for patients seeking effective treatments, ultimately impacting the overall progress and availability of CNS therapeutics.
Market Trends of the CNS (Central Nervous System) Therapeutics Market
The Central Nervous System (CNS) therapeutics market is witnessing a significant shift towards personalized medicine, driven by advancements in genetics and neuroimaging technologies. This trend enables healthcare providers to tailor treatments to individual patients based on their unique genetic profiles and neurobiological characteristics, resulting in more precise and effective interventions. By focusing on personalized approaches, the market aims to improve treatment outcomes for prevalent CNS disorders such as Alzheimer's, depression, and schizophrenia while reducing adverse effects associated with traditional therapies. As this paradigm evolves, it holds the potential to transform the landscape of CNS therapeutics, enhancing patient care and efficacy.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global CNS (Central Nervous System) Therapeutics Market Size by Disease & CAGR (2025-2032)
Market Overview
Neurovascular Diseases
CNS Trauma
Mental Health
Anxiety Disorders
Epilepsy
Mood Disorders
Psychotic Disorders
Others
Neurodegenerative Diseases
Alzheimer's Disease
Parkinsosn's Disease
Multiple Sclerosis
Huntington's Disease
Amytrophic Lateral Sclerosis
Others
Infectious Diseases
CNS Cancer
Others
Global CNS (Central Nervous System) Therapeutics Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Anesthetics
Anticonvulsants
Antiemetics
CNS Stimulants
Pain Relievers
Others
Global CNS (Central Nervous System) Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)
